

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
2 August 2001 (02.08.2001)

PCT

(10) International Publication Number  
**WO 01/54685 A1**

(51) International Patent Classification<sup>7</sup>: **A61K 31/192,**  
31/195, 31/443, 31/47, 31/5415

[US/US]; 5110 Campus Drive, Meeting House, PA 19462 (US). **LEVITT, Roy, C.** [US/US]; 5110 Campus Drive, Meeting House, PA 19462 (US). **NICOLAIDES, Nicholas, C.** [US/US]; 5110 Campus Drive, Meeting House, PA 19462 (US). **JONES, Steve** [US/US]; 5110 Campus Drive, Meeting House, PA 19462 (US). **MCLANE, Mike** [US/US]; 5110 Campus Drive, Meeting House, PA 19462 (US).

(21) International Application Number: PCT/US01/03078

(22) International Filing Date: 31 January 2001 (31.01.2001)

(25) Filing Language: English

(26) Publication Language: English

(74) Agent: **CARROLL, Lawrence**; Morgan, Lewis & Bockius LLP, 1800 M Street, N.W., Washington, DC 20036 (US).

(30) Priority Data:

60/179,127	31 January 2000 (31.01.2000)	US
60/193,111	30 March 2000 (30.03.2000)	US
60/230,783	7 September 2000 (07.09.2000)	US
60/242,134	23 October 2000 (23.10.2000)	US
60/252,052	20 November 2000 (20.11.2000)	US

(81) Designated States (national): AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW.

(71) Applicant (for all designated States except US): **MAGAININ PHARMACEUTICALS, INC.** [US/US]; 5110 Campus Drive, Meeting House, PA 19462 (US).


(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian

(72) Inventors; and  
(75) Inventors/Applicants (for US only): **ZHOU, Yuhong**

*[Continued on next page]*

(54) Title: MUCIN SYNTHESIS INHIBITORS

D 01/54685 A1



(57) Abstract: The claimed invention relates to methods of modulating mucin synthesis and the therapeutic application of com-



patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

*For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

**Published:**

-- *with international search report*

## MUCIN SYNTHESIS INHIBITORS

### CROSS-REFERENCE TO RELATED APPLICATIONS

This application claims the benefit of U.S. Provisional Application 60/179,127, filed on January 31, 2000, Provisional Application 60/193,111, filed on March 30, 2000, Provisional Application 60/230,783, filed September 7, 2000, Provisional Application 60/ filed October 23, 2000 and Provisional Application 60/ filed November 20, 2000 all of which are herein incorporated by reference in their entirety. All of the above referenced applications are entitled "Mucin Synthesis Inhibitors" and the inventors are Yuhong Zhou, Roy C. Levitt, Nicholas C. Nicolaides, Steve Jones, and Mike McLane.

This invention is also related to the subject matter of U.S. Patent Application  
5 08/702,110, filed on August 23, 1996, issued on March 14, 2000, as U.S. Patent No. 6,037,149 and is related to U.S. Patent Application 09/325,571, filed on June 9, 1999 and U.S. Patent No. 5,908,839 issued June 1, 1999 all of which are all herein incorporated by reference in their entirety. In addition, this application is related to U.S. Patent Application 08/980,872, filed December 1, 1997, which is herein incorporated by  
10 reference in its entirety.

### FIELD OF THE INVENTION

This invention relates to methods of modulating mucin synthesis and the therapeutic application of compounds in controlling mucin over-production associated  
15 with diseases such as asthma, chronic bronchitis, inflammatory lung diseases, cystic fibrosis and acute or chronic respiratory infectious diseases as well as chronic obstructive pulmonary diseases (COPD).

## BACKGROUND OF THE INVENTION

The airway epithelium is known to play an integral role in the airway defense mechanism via the mucociliary system and mechanical barriers. Recent studies indicate that airway epithelial cells (AEC) can be activated to produce and release biological mediators important in the pathogenesis of multiple airway disorders (Polito and Proud, 1998; Takizawa, 1998). Evidence has shown that the epithelium is fundamentally disordered in chronic airway disorders such as asthma, chronic bronchitis, emphysema, and cystic fibrosis (Holgate *et al.*, 1999; Jeffery PK, 1991; Salvato, 1968; Glynn and Michaels, 1960). One of the hallmarks of these airway disorders is the over-production of mucus by AEC. The major macromolecular components of mucus are the large glycoproteins known as mucins. Recently, the molecular structure of at least 7 human mucins was determined. The known mucin transcripts are heterogeneous with no sequence homology between the genes (Voynow and Rose, 1994), yet they are similar in their overall repetitive structure.

Deleterious stimuli are known to activate AEC. These stimuli can vary from antigens in allergic disease to drugs or environmental pollutants, tobacco smoke, and infectious agents associated with forms of chronic obstructive pulmonary disease. AEC activation leads to altered ion transport, changes in ciliary beating, and the increased production and secretion of mucins leading to increased mucus. The mediators produced in response to AEC activation include chemokines that promote the influx of inflammatory cells (Takizawa, 1998). These inflammatory cells can in turn produce mediators that may injure AEC. AEC injury stimulates cellular proliferation (goblet cell and submucosal gland cell hyperplasia) that results in an expanded and continuous source of pro-inflammatory products, including proteases as well as growth factors that drive airway wall remodeling that can lead to lung destruction and the loss of function (Holgate *et al.*, 1999).

The over-production of mucus and alteration of its physiochemical characteristics can contribute to lung pathology in a number of ways. Disruption of physiologic mucociliary clearance by the over-production of mucins can lead to mucus plugging, air trapping, and atelectasis which is often complicated by infection.

-3-

Asthma is a chronic obstructive lung disorder that appears to be increasing in prevalence and severity (Gergen and Weiss, 1992). It is estimated that 30-40% of the population suffers with atopic allergy and 15% of children and 5% of adults in the population suffer from asthma (Gergen and Weiss, 1992).

5 In asthma, activation of the immune system by antigens leads to allergic inflammation. When this type of immune activation occurs it is accompanied by pulmonary inflammation, bronchial hyperresponsiveness, goblet cell and submucosal gland hyperplasia, and mucin over-production and hyper-secretion (Basle *et al.*, 1989) (Pailasse, 1989) (Bosque *et al.*, 1990). Mucus over-production and plugging associated  
10 with goblet cell and submucosal gland cell hyperplasia is an important part of the pathology of asthma and has been described on examination of the airways of both mild asthmatics and individuals who have died with status asthmaticus (Earle, 1953) (Cardell and Pearson, 1959) (Dunnill, 1960) (Dunnill *et al.*, 1969) (Aikawa *et al.*, 1992) (Cutz *et al.*, 1978). Certain inflammatory cells are important in this reaction including T cells,  
15 antigen presenting cells, B cells that produce IgE, basophils that bind IgE, and eosinophils. These inflammatory cells accumulate at the site of allergic inflammation and the toxic products they release contribute to the destruction of AEC and other tissues related to these disorders.

In the related patent applications mentioned above, applicants have demonstrated  
20 that interleukin-9 (IL9), its receptor and activities effected by IL9 are the appropriate targets for therapeutic intervention in atopic allergy, asthma and related disorders. Mediator release from mast cells by allergen has long been considered a critical initiating event in allergy. IL9 was originally identified as a mast cell growth factor and it has been demonstrated that IL9 up-regulates the expression of mast cell proteases including MCP-1,  
25 MCP-2, MCP-4 (Eklund *et al.*, 1993) and granzyme B (Louahed *et al.*, 1995). Thus, IL9 appears to serve a role in the proliferation and differentiation of mast cells. Moreover, IL9 up-regulates the expression of the alpha chain of the high affinity IgE receptor (Dugas *et al.*, 1993). Furthermore, both *in vitro* and *in vivo* studies have shown IL9 to potentiate the release of IgE from primed B cells (Petit-Frere *et al.*, 1993).

30 Recently, IL9 was shown to stimulate mucin synthesis and may account for as much as 50-60% of the mucin-stimulating activity of lung fluids in allergic airway disease

-4-

(Longpre *et al.*, 1999). A gross up-regulation of mucin synthesis and mucus over-production occurs in IL9 transgenic mice as compared to mice from the background strain. IL9 specifically up-regulates the MUC2 and MUC5AC genes and proteins *in vitro* and *in vivo* (Louahed *et al.*, 2000). Moreover, IL9 neutralizing antibody inhibits completely the 5 up-regulation of mucins in response to antigen challenge in animal models of asthma (McLane *et al.*, 2000)

Current asthma treatments suffer from a number of disadvantages. The main therapeutic agents, beta-receptor agonists, reduce the symptoms thereby transiently improving pulmonary function, but do not affect the underlying inflammation nor do they 10 suppress mucin production. In addition, constant use of beta-receptor agonists results in desensitization, which reduces their efficacy and safety (Molinoff *et al.*, 1995). The agents that can diminish the underlying inflammation, and thereby decrease mucin production, such as anti-inflammatory steroids, have their own list of disadvantages that range from immunosuppression to bone loss (Molinoff *et al.*, 1995).

15 Chronic bronchitis is another form of chronic obstructive pulmonary disorder. Nearly 5% of adults suffer with this pulmonary disorder. Chronic bronchitis is defined as the chronic over-production of sputum. Mucus over-production is generally associated with inflammation of the conducting airways. The mediators of inflammatory cells including neutrophils and macrophages may be associated with increased mucin gene expression in this disorder (Voynow *et al.*, 1999; Borchers *et al.*, 1999). The increased 20 production of mucus is associated with airway obstruction, which is one of the cardinal features of this pulmonary disorder. Therapy is largely symptomatic and focused on controlling infection and preventing further loss of lung function. Decongestants, expectorants and combinations of these agents that are often used to treat the symptoms of 25 bronchitis are not thought to alter mucin production. Mucolytics may promote mucociliary clearance and provide symptomatic relief by reducing the viscosity and/or the elasticity of the airway secretions but do not inhibit mucin synthesis or mucus over-production. (Takahashi *et al.*, 1998)

Cystic fibrosis (CF) is yet another disease that effects the lung and is associated 30 with thick secretions resulting in airway obstruction and subsequent colonization and infection by inhaled pathogenic microorganisms (Eng *et al.*, 1996). DNA levels are

-5-

increased significantly in CF lung and can increase the viscosity of sputum. While recombinant aerosolized DNase is of value in these patients, there is no effective treatment for the pathologic mucus over-production. Thus, there is a specific unmet need in the art for the identification of agents capable of inhibiting mucin over-production by

5 airway epithelial cells in CF. In addition to the airway obstruction caused by mucin secretions, CF patients also suffer from mucus plugging in the pancreatic ducts which prevent the delivery of digestive enzymes to the GI tract. The result is malabsorption syndrome, steatorrhea and diarrhea.

While mucus over-production is one of the hallmarks of multiple chronic  
10 obstructive lung disorders, the art lacks any methods to block the synthesis or over-production of mucins associated with these pulmonary disorders. Thus, there is a specific need in the art to inhibit the over-production of mucins and thin the secretions of these patients to promote mucociliary clearance and preserve lung function.

15

## SUMMARY OF THE INVENTION

The current invention relates to the discovery of agents that inhibit the synthesis and over-production of mucin glycoproteins and methods of using these molecules to treat the pathologic over-production of mucus in chronic obstructive pulmonary disorders and  
20 other diseases.

In one aspect, the present invention provides a method of treating a subject with a respiratory disease characterized by the production of mucin, comprising administering to the subject an effective amount of a composition comprising at least one compound that decreases mucin synthesis or levels in the lungs or in the GI tract. In some embodiments,  
25 the mucin synthesis may be chloride channel dependent. In some embodiments, the compound decreases mucin synthesis in cells that express an ICACC chloride channel. In some embodiments, the compound is selected from a group consisting of analogues and derivatives of anthranilic acid, analogues and derivatives of 2-amino-nicotinic acid, analogues and derivatives of 2-amino-phenylacetic acid, bendroflumethiazide, salts thereof  
30 and prodrugs thereof. In some preferred embodiments, the compound is selected from the group consisting of talniflumate, flufenamic acid, niflumic acid, mefenamic acid, salts

thereof, derivatives thereof and prodrugs thereof. In some preferred embodiments, the compositions of the present invention comprise talniflumate, a talniflumate derivative, a salt thereof or a prodrug thereof.

In some embodiments, the compositions of the present invention may comprise at least one compound that decreases mucin synthesis or levels in the lungs or in the GI tract wherein the compound is a quinoline or quinoline derivative. In some embodiments, the compound may be a quinoline modified with an amine group, preferably at the 2 or 3 position of the quinoline. In a preferred embodiment, the compound may be a 3-amino-quinoline in which the exocyclic nitrogen is modified with one or more moieties. In some embodiments, the exocyclic amine group may be modified with an aromatic moiety. The aromatic moiety may be modified or unmodified. In a preferred embodiment, the aromatic group is a benzyl group which may be modified with one or more substituents. Suitable substituents include, but are not limited to, halogens. In a preferred embodiment, the compound is an N-(fluorobenzyl)-3-amino-quinoline (Figure 19), preferably the fluorine is in the meta position.

In another aspect of the present invention the compounds that decrease mucin synthesis are also inhibitors of the enzyme cyclooxygenase such as talniflumate. In a more preferred embodiment the compounds are specific inhibitors of the enzyme cyclooxygenase-2.

In another embodiment, the present invention provides a method of treating a subject with a respiratory disease characterized by the production of mucin by administering the compositions of the invention by inhalation. In some embodiments, the composition is in the form of a liquid or in the form of a powder. In some embodiments, the composition is aerosolized. In other embodiments, the composition further comprises at least one expectorant, antihistamine, mucolytic agent, antibiotic or decongestant agent. In some embodiments, the expectorant is guaifenesin. The compositions of the invention may further comprise at least one stabilizing agent, absorption-enhancing agent or flavoring agent. In some preferred embodiments, the stabilizing agent is cyclodextran and/or the absorption-enhancing agent is chitosan.

In some preferred embodiments, the compositions and methods of the present invention may be used to treat a respiratory disease selected from the group consisting of a

chronic obstructive pulmonary disease (COPD), an inflammatory lung disease, cystic fibrosis and an acute or chronic infectious disease. The treatment of any one of these diseases may be by administering one or more of the compositions of the invention via inhalation. In some embodiments, the composition is administered via inhalation to the 5 lungs. In preferred embodiments, the present invention provides methods and materials to treat a COPD selected from the group consisting of emphysema, chronic bronchitis and asthma.

In another preferred embodiment, the compositions and methods of the present invention may be used to treat the GI complications of cystic fibrosis such as 10 malabsorption syndrome, steatorrhea and diarrhea. The treatment of this disease may be by administering one or more of the compositions of the invention orally.

In another embodiment, the present invention provides a therapeutic composition formulated for inhalation delivery comprising an amount effective to decrease mucin production or levels of at least one compound selected from the group consisting of 15 talniflumate, flufenamic acid, niflumic acid, mefenamic acid, salts thereof, derivates thereof and prodrugs thereof. In some preferred embodiments, the composition comprises talniflumate, a talniflumate derivative, a salt thereof or a prodrug thereof. In some embodiments, the composition is in the form of a liquid or in the form of a powder. In some embodiments, the composition further comprises at least one expectorant, mucolytic 20 agent, antibiotic, anti-histamine or decongestant agent. In some embodiments, the expectorant is guaifenesin.

In addition to the agents described above, the pharmaceutical compositions of the present invention formulated for inhalation may further comprise at least one stabilizing 25 agent, absorption-enhancing agent or flavoring agent. In some embodiments, the stabilizing agent is a cyclodextran and/or the absorption-enhancing agent is chitosan.

The present invention also provides an inhalation device comprising a therapeutic composition as described above.

#### BRIEF DESCRIPTION OF THE FIGURES

Figure 1 shows the effect of NFA on mucin production. NFA inhibitor blocks mucin overproduction *in vitro*.

-8-

Figure 2 shows the ability of NFA and various compounds to suppress the over-production of mucin by activated Caco2 cells. This figure shows the inhibition of mucin production in activated Caco2 cells by fenamates.

Figure 3 shows that treatment of the activated Caco2 cell line with NFA did not  
5 effect their viability. This figure shows that NFA does not effect epithelial cell proliferation.

Figure 4 shows the inhibition of epithelial cell production of the chemokine eotaxin. This figure shows that NFA blocks epithelial activation including chemokine production.

10 Figure 5 shows that intra-tracheal administration of NFA suppresses antigen-induced airway hyperresponsiveness (Af + NFA) compared to phosphate buffered saline (PBS). This figure shows that NFA blocks epithelial antigen responses including airway hyperresponsiveness.

15 Figure 6 shows the results of intra-tracheal administration of NFA. This figure shows that NFA reduces antigen-induced lung eosinophilia *in vivo*. This is seen by comparing eosinophilia after activation with Aspergillus in the presence of NFA (Af + NFA) to eosinophilia after activation in the absence of NFA phosphate buffered saline (Af +PBS).

20 Figure 7 shows the results of intra-tracheal administration of NFA on antigen-induced increases in mucus (mucin glyco-conjugates) (Af + NFA) compared to phosphate buffered saline (PBS). This figure shows NFA blocks increased mucin expression due to antigen in the lungs of exposed mouse.

Figure 8 shows that IL9 transgenic mice constitutively over-produce mucin in the airway in contrast to control FVB mice.

25 Figure 9 shows the constitutive over-production of mucin in the lung of IL9 transgenic mice is associated with the specific up-regulation of MUC2 and MUC5AC steady-state transcripts compared to the background strain (FVB/NJ) of mice. This figure shows that specific mucin genes are up-regulated in the lungs of IL-9 transgenic mice.

30 Figure 10 shows the effect of anti-IL-9 antibody on mucin over-production in the lung of antigen-exposed mice. This figure shows neutralizing IL-9 antibody prevents mucin over-production in antigen-exposed mice.

-9-

Figure 11 shows a generic formula for phenyl anthranilic acid analogues that block mucin production wherein

X<sub>1</sub> to X<sub>9</sub>= each independently of the others may be C, S, O or N,

R<sub>1</sub> to R<sub>11</sub>= each independently of the others may be hydrogen, alkyl, aryl, substituted alkyl,

5 substituted aryl, halogen, halogen substituted alkyl, halogen substituted aryl, alkyl or aryl forming a ring, substituted alkyl or aryl forming a ring, hydroxyl, alkyl or aryl ether, amine, alkyl or aryl amine, alkyl or aryl ester, alkyl or aryl sulfonamide, thiol, alkyl or aryl thioether, alkyl or aryl sulfone, alkyl or aryl sulfoxide or sulfonamide,

Y= carboxylate, alkyl carboxylate, sulfate, sulfonate, phosphate, phosphonate, amides of

10 carboxylic acids, esters of carboxylic acids, amides of phosphoric acids, esters of phosphoric acids, amides of sulfonic acids, esters of sulfonic acids, amides of phosphonic acids , esters of phosphonic acids, sulfonamide, phosphonamide, tetrazole, hydroxamic acid or other acid isostere,

Z =O, NR<sub>10</sub>, S, CR<sub>10</sub>R<sub>11</sub>, sulfoxide or sulfone,

15 m= 0 or 1,

n=1 or 2.

Figure 12 shows mucin expression induced by hICACC-1 in NCI-H292 cells.

Figure 13 shows mucus over-production in NCI-H292 cells over-expressing hICACC-1.

20 Figure 14 shows the inhibition of mucin production by Talniflumate.

Figures 15 A & B show the inhibition of mucin over production by oral administration if Talniflumate in mice. Figure 15A shows a section of lung (stained with H&E) from a mouse sensitized to *Aspergillus fumigatus* and allowed access to regular mouse chow. Figure 15B shows a section of lung (stained with H&E) from a mouse sensitized with *Aspergillus fumigatus* and allowed access to Talniflumate-containing mouse chow.

25 Figure 16 shows the inhibition of lung eosinophilia by oral administration if Talniflumate in mice. This figure shows AHR373: the effect of Talniflumate mouse chow on BAL of B6D2F1/J male mice sensitized with *Aspergillus fumigatus*.

30 Figure 17 shows the inhibition of MUC5A/C secretion by Nimesulide.

Figure 18 shows the inhibition of MUC5A/C secretion by MSI-2079.

-10-

Figure 19 shows the structure of MSI-2079.

## DETAILED DESCRIPTION OF THE INVENTION

The present invention is, in part, derived from the finding that mucus over-production resulting from activation of nonciliated epithelial cells of the lung is caused by induction of mucin genes including MUC2 and MUC5AC. Thus, one aspect of the invention is the inhibition of epithelial cell activation. This inhibition of AEC activation down-regulates chemokine production, bronchial responsiveness, and mucin gene expression. Molecules that decrease mucin synthesis or levels are therefore part of the invention.

### *Agents that Decrease Mucin Synthesis or Levels*

As described herein, the formulations and compositions of the invention include agents that decrease mucin synthesis or levels, or decrease in some way the over-production of mucin. As used herein, "decrease" is defined as a down-regulation in the level, activation, function, stability, or synthesis of mucin. Preferred agents decrease the chloride channel dependent level, activation, function, stability, or synthesis of mucin. As used herein, "chloride channel" refers to, but is not limited to, the ICACC chloride channel and the related channels referred to in WO 99/44620, which is herein incorporated by reference in its entirety. Agents that fall under these definitions may be identified or their activity verified by screening in the assays described in the Examples. For instance, the *in vitro* and *in vivo* assays described in Examples 7 and 8 may be used to screen, identify or verify an agent's activity.

Molecules that decrease mucin synthesis or levels include analogues and derivatives of anthranilic acid (2-aminobenzoic acid). In some preferred embodiments, the molecule may be an N-derivatized anthranilic acid. In some embodiments, the amino group of anthranilic acid may be modified with one or more groups. In some embodiments, the group may be an aromatic group. In a preferred embodiment, the group may be a trifluoromethyl-phenyl group preferably a 3-trifluoromethyl-phenyl group and the molecule that decreases mucin synthesis or levels is flufenamic acid. In another preferred embodiment, the amino group may be derivatized with a 2,3-dimethyl-phenyl

group and the molecule that decreases mucin synthesis or levels is mefenamic acid. Those skilled in the art will appreciate that other phenyl derivatives of anthranilic acid may be used in the present invention. In other preferred embodiments, the benzoic acid ring may include one or more substituents. In a preferred embodiment, both the benzoic acid ring and the amino group may be modified. Other preferred embodiments, include molecules having substituents on the benzoic acid ring and aromatic groups attached to the amino group.

In some embodiments, the molecules that decrease mucin synthesis include analogues and derivatives of 2-amino-nicotinic acid. In some embodiments the exocyclic amino group may be modified to include one or more groups. In some preferred embodiments, the exocyclic amine group may be modified with an aromatic group. Suitable aromatic groups include, but are not limited to, a phenyl group, a modified phenyl group, a benzyl group, a modified benzyl group and the like. In a preferred embodiment, the aromatic group may be a 3-trifluoromethyl-phenyl group and the derivative of 2-amino-nicotinic acid is niflumic acid.

In some embodiments, the molecule that decreases mucin synthesis may be an analogue or derivative of 2-amino-phenylacetic acid. In some embodiments, the amino group may be modified to include one or more groups. In some embodiments, the amino group may be modified with an aromatic group. Suitable aromatic groups include, but are not limited to, a phenyl group, a modified phenyl group, a benzyl group, a modified benzyl group and the like. In a preferred embodiment, the 2-amino-phenylacetic acid is N-modified with a 2, 6-dichlorophenyl group and the molecule that decreases mucin synthesis or levels is talniflumate.

In some embodiments, the molecule that decreases mucin synthesis or levels may be bendroflumethiazide.

The present invention also contemplates the use of prodrugs of one or more of the above-mentioned molecules that decrease mucin synthesis or levels. As defined herein, a prodrug is a molecule that is administered in a form other than that described above and is converted in the body of the subject into the form described. Preferred prodrugs include, but are not limited to, prodrugs of fenamates. Some preferred prodrugs are esters of the acid form of the molecule that decreases mucin synthesis or levels. Preferred esters

-12-

include, but are not limited to, esters of NFA, for example, the beta-morpholinoethyl ester, morniflumate, and the phthalidyl ester, talniflumate.

*Uses for Agents that Modulate the Production of Mucin.*

5 As provided in the Examples, agents that modulate, decrease or down-regulate the expression of mucin may be used to modulate biological and pathologic processes associated with mucin production.

Applicants have observed that IL9 selectively induces the expression of mucin gene products. Thus, the pleiotropic role for IL9, which is important to a number of 10 antigen-induced responses, is dependent in part, on the up-regulation of mucin in AEC. When the functions of IL9 are down-regulated by neutralizing antibody treatment, animals can be completely protected from antigen-induced responses in the lung. These responses include: bronchial hyperresponsiveness, eosinophilia and elevated cell counts in bronchial lavage, elevated serum IgE, histologic changes in lung associated with inflammation, and 15 goblet cell and submucosal gland cell hyperplasia associated with the over-production of mucus. The down-regulation of IL9 and asthmatic-like responses is associated with the down-regulated expression of mucin (Figure 10). Thus, treatment of such responses, which underlie the pathogenesis of asthma and characterize allergic inflammation 20 associated with this disorder, by down-regulating mucin production, is within the scope of this invention.

Histologic analysis of IL9 transgenic mice airways has shown mucin over-production in nonciliated epithelial cells (Temann *et al.*, 1998; Louahed *et al.*, 2000). Induction of mucin in the IL9 transgenic mouse lung suggests that IL9 promotes mucus production by these cells (see Figure 8). Activated Caco2 cells that express the mRNA of 25 MUC1, MUC2, MUC3, MUC4, MUC5B and MUC5AC have been produced and used to test for inhibitors of mucin production. These cells can be stained for mucin using Periodic Acid-Schiff staining (PAS). As shown in Figure 1A, the untreated activated Caco2 cells stain intensely for PAS positive mucin glycoconjugates. Control and activated cells were cultured in the presence of niflumic acid (NFA) or 4,4'-diisothiocyanostilbene-30 2,2'-disulfonic acid (DIDS). PAS staining of inhibitor treated activated cells revealed

-13-

significantly fewer positive staining glycoconjugates as compared with the untreated cells (Figure 1D compared to 1B).

While a therapeutic potential for mucin down-regulation has been identified in asthma, Applicants have also recognized a therapeutic potential for down-regulation of 5 mucin in cystic fibrosis. Patients with cystic fibrosis are hampered by lung disease characterized by thick secretions, which cause airway obstruction and subsequent colonization and infection by inhaled pathogenic microorganisms (Eng *et al.*, 1996). Applicants therefore provide a method for treating cystic fibrosis by down regulating mucin production in the lung.

10 Mucin over production in cystic fibrosis is also present in the pancreatic ducts that deliver digestive enzymes to the GI tract resulting in malabsorption syndrome, steatorrhea and diarrhea. Applicants therefore also provide a method for treating cystic fibrosis by down regulating mucin production in the pancreas.

15 Applicants have also identified a therapeutic potential for mucin down-regulation in chronic bronchitis and emphysema. Patients with chronic bronchitis and emphysema are hampered by lung disease characterized by thick secretions, which cause airway obstruction and subsequent colonization and infection by inhaled pathogenic microorganisms (Eng *et al.*, 1996). Applicants therefore provide a method for treating chronic bronchitis and emphysema by down regulating mucin production in the lung.

20 As used herein, a subject can be any mammal, so long as the mammal is in need of modulation of a pathological or biological process mediated by mucin production. The term "mammal" is meant as an individual belonging to the class Mammalia. The invention is particularly useful in the treatment of human subjects.

25 Pathological processes refer to a category of biological processes that produce a deleterious effect. For example, mucin over-production of the invention may be associated with respiratory disease, including chronic obstructive pulmonary disease (COPD), inflammatory lung disease, cystic fibrosis and an acute or chronic infectious disease. COPD includes, but is not limited to bronchitis, asthma and emphysema. Mucin over-production may also be associated with GI diseases such as malabsorption 30 syndrome, steatorrhea and diarrhea that are present in cystic fibrosis.

-14-

As used herein, an agent is said to modulate a pathological process when the agent reduces the degree or severity of the process. For instance, airway obstruction may be prevented or disease progression modulated by the administration of agents that reduce or modulate in some way the synthesis, levels and/or over-production of mucin.

5

#### *Therapeutic Compositions*

The agents of the present invention can be provided alone, or in combination with other agents that modulate a particular pathological process. For example, an agent of the present invention can be administered in combination with anti-asthma agents. In another 10 embodiment, an agent may be administered in combination with expectorants, mucolytics, antibiotics, antihistamines or decongestants. In still another embodiment, an agent may be administered along with a surfactant, a stabilizing agent, an absorption-enhancing agent, a beta adrenoreceptor or purine receptor agonist or a flavoring or other agent that increases 15 the palatability of the compositions. As an example, compositions of the invention may contain, in addition to the active agent, an expectorant such as guaifenesin, a stabilizing agent such as cyclodextran and/or an absorption-enhancing agent such as chitosan. Any such agents may be used in the compositions of the invention.

As used herein, two or more agents are said to be administered in combination when the agents are administered simultaneously or are administered independently in a 20 fashion such that the agents will act at the same time.

The agents of the present invention can be administered via parenteral, subcutaneous, intravenous, intramuscular, intraperitoneal, transdermal, topical, or buccal routes. Alternatively, or concurrently, administration may be by the oral or nasal route or directly to the lungs. In a preferred embodiment, the compounds of this invention may be 25 administered by inhalation. For inhalation therapy the compound may be in a solution useful for administration by liquid aerosol, metered dose inhalers, or in a form suitable for a dry powder inhaler. The dosage administered will be dependent upon the age, health, and weight of the recipient, kind of concurrent treatment, if any, frequency of treatment, and the nature of the effect desired.

30 In some preferred embodiments, the agents of the present invention may be formulated as aerosols. The formulation of pharmaceutical aerosols is routine to those

-15-

skilled in the art, see for example, Sciarra, J. in Remington: The Science and Practice of Pharmacy 19<sup>th</sup> Edition, Chapter 95, Mack Publishing Company, Easton, PA. The agents may be formulated as solution aerosols, dispersion or suspension aerosols of dry powders, emulsions or semisolid preparations. The aerosol may be delivered using any propellant 5 system known to those skilled in the art. The aerosols may be applied to the upper respiratory tract, for example by nasal inhalation, or to the lower respiratory tract or to both.

The compounds used in the method of treatment of this invention may be administered systemically or topically, depending on such considerations as the condition 10 to be treated, need for site-specific treatment, quantity of drug to be administered and similar considerations.

Any common topical formation such as a solution, suspension, gel, ointment or salve and the like may be employed. Preparation of such topical formulations are well described in the art of pharmaceutical formulations as exemplified, for example, by 15 Remington's Pharmaceutical Sciences. For topical application, these compounds could also be administered as a powder or spray, particularly in aerosol form. The active ingredient may be administered in pharmaceutical compositions adapted for systemic administration. As is known, if a drug is to be administered systemically, it may be confected as a powder, pill, tablet or the like or as a syrup or elixir for oral administration. 20 For intravenous, intra-peritoneal or intra-lesional administration, the compound will be prepared as a solution or suspension capable of being administered by injection. In certain cases, it may be useful to formulate these compounds in suppository form or as an extended release formulation for deposit under the skin or intra-muscular injection.

An effective amount of a composition or agent contained therein is that amount 25 that will reduce, decrease or down-regulate mucin activation, function, stability, or synthesis. Preferred compositions or agents reduce, decrease or down-regulate chloride channel dependent mucin activation, function, stability, or synthesis, including ICACC chloride channel dependent mucin activation, function, stability, or synthesis. A given effective amount will vary from condition to condition and in certain instances may vary 30 with the severity of the condition being treated and the patient's susceptibility to treatment. Accordingly, a given effective amount will be best determined at the time and place

through routine experimentation. It is anticipated, however, that in the treatment of chronic obstructive pulmonary disorders in accordance with the present invention, a formulation containing between 0.001 and 5 percent by weight, preferably about 0.01 to 1%, will usually constitute a therapeutically effective amount. When administered 5 systemically, an amount between 0.01 and 100 mg per kg body weight per day, but preferably about 0.1 to 10 mg/kg/day, will effect a therapeutic result in most instances.

When administered via inhalation, an amount between 0.01 and 100 mg per kg body weight per day, but preferably about 0.10 to 10 mg/kg/day, will effect a therapeutic result in most instances. In some instances, a metered dose aerosol unit contains about 0.8 10 mg of a compound of the present invention, for instance, talniflumate. At this formulation, the maintenance dose for an adult is about 2 inhalations (about 1.6 mg) twice daily (about 3.2 mg).

The invention also includes pharmaceutical compositions comprising the compounds of the invention together with a pharmaceutically acceptable carrier. 15 Pharmaceutically acceptable carriers can be sterile liquids, such as water and oils, including those of petroleum, animal, vegetable or synthetic origin, such as peanut oil, soybean oil, mineral oil, sesame oil and the like. Water is a preferred carrier when the pharmaceutical composition is administered intravenously or by inhalation. Saline or phosphate buffered saline can also be employed as carriers, particularly for inhalation by 20 aerosols. Lactated saline solutions and aqueous dextrose and glycerol solutions can also be employed as liquid carriers, particularly for injectable solutions. Suitable pharmaceutical carriers are described in Remington's Pharmaceutical Sciences, Mack Publishing Company, 1995.

In addition to the pharmacologically active agent, the compositions of the present 25 invention may contain suitable pharmaceutically acceptable carriers comprising excipients and auxiliaries that facilitate processing of the active compounds into preparations that can be used pharmaceutically for delivery to the site of action. Suitable formulations for parenteral administration include aqueous solutions of the active compounds in water-soluble form, for example, water-soluble salts. In addition, suspensions of the active 30 compounds as appropriate oily injection suspensions may be administered. Suitable lipophilic solvents or vehicles include fatty oils, for example, sesame oil, or synthetic fatty

-17-

acid esters, for example, ethyl oleate or triglycerides. Aqueous injection suspensions may contain substances which increase the viscosity of the suspension include, for example, sodium carboxymethyl cellulose, sorbitol, and/or dextran. Optionally, the suspension may also contain stabilizers as described above. Liposomes can also be used to encapsulate the 5 agent for delivery into the cell.

The pharmaceutical formulation for systemic administration according to the invention may be formulated for enteral, parenteral or topical administration. Indeed, all three types of formulations may be used simultaneously to achieve systemic administration of the active ingredient.

10 Suitable formulations for oral administration include hard or soft gelatin capsules, pills, tablets, including coated tablets, elixirs, suspensions, syrups or inhalations and controlled release forms thereof. Suitable formulations for oral inhalation or nasal inhalation include aqueous solutions with or without excipients well known in the art.

15 Therapeutic or pharmaceutical compositions or formulations of the invention may be packaged in containers, vials, inhalation devices, etc. with instructions or labels addressing the ability of the composition or formulation to promote lower respiratory tract drainage by thinning bronchial secretions, lubricating irritated respiratory tract membranes through increased mucous flow and/or facilitating the decreased production and removal of viscous, inspissated mucus. The label or instruction may also address indications and 20 usage such as the maintenance of symptomatic relief of various conditions as herein described, including but not limited to, moderate to severe asthma, chronic bronchitis, cystic fibrosis, upper and lower respiratory tract infections and other conditions complicated by the persistence of viscous mucus in the respiratory tract or other places in the body.

25 The devices of the present invention may be any device adapted to introduce one or more therapeutic compositions into the upper and/or lower respiratory tract. In some preferred embodiments, the devices of the present invention may be metered-dose inhalers. The devices may be adapted to deliver the therapeutic compositions of the invention in the form of a finely dispersed mist of liquid, foam or powder. The devices may use any 30 propellant system known to those in the art including, but not limited to, pumps, liquefied-gas, compressed gas and the like. Devices of the present invention typically comprise a

-18-

container with one or more valves through which the flow of the therapeutic composition travels and an actuator for controlling the flow. Suitable devices for use in the present invention may be seen in, for example, in Remington: The Science and Practice of Pharmacy, 19<sup>th</sup> Edition, Chapter 95, pages 1676-1692, Mack Publishing Co., Easton, PA  
5 1995.

The practice of the present invention may employ the conventional terms and techniques of molecular biology, pharmacology, immunology and biochemistry that are within the ordinary skill of those in the art. For example, see Sambrook *et al.*, Molecular Cloning: A Laboratory Manual, 2nd edition, Cold Spring Harbor Laboratory Press, 1985.

10 Without further description, it is believed that one of ordinary skill in the art can, using the preceding description and the following illustrative examples, make and utilize the compounds of the present invention and practice the claimed methods. The following working examples therefore, specifically point out preferred embodiments of the present invention, and are not to be construed as limiting in any way the remainder of the  
15 disclosure.

### Examples

Example 1: *NFA inhibits mucin production by Caco2 cells activated to over-produce mucin*

20 Activated Caco2 cells that express the mRNA of MUC1, MUC2, MUC3, MUC4, MUC5B and MUC5AC have been produced and used to test for inhibitors of mucin production. These cells can be stained for mucin using Periodic Acid-Schiff staining (PAS). As shown in Figure 1, although Caco2 control cells displayed a basal PAS staining with a few small glycoconjugates vesicles scattered about (panel A), activation of the  
25 Caco2 cells dramatically increased the number and intensity of PAS positive mucin glycoconjugates (panel B). The activated Caco2 cells were cultured in the presence of niflumic acid (NFA) or 4,4'-diisothiocyanostilbene-2,2'-disulfonic acid (DIDS). At the indicated concentrations (100 µm for NFA and 300 µm for DIDS), PAS staining of inhibitor treated activated Caco2 cells revealed significantly fewer positive staining mucin  
30 glycoconjugates as compared with the untreated cells (Figure 1D compared to 1B). In addition, the slight staining seen in control cells was also inhibited (Figure 1C compared to

-19-

1A). Mucin production by activated Caco2 cells could also be inhibited by other fenamates such as Flufenamate (FFA), Tolfenamate (TFLA) and partially by Mefenamate (MFA) and Meclofenamate (MLFA) (Figure 2). Related compounds Naproxen (MMNA) and Sulindac were ineffective. This reduced mucin production in NFA treated cells was  
5 not due to dramatic changes of the physiological condition of the cells, since their viability was not affected by even higher concentrations of NFA (Figure 3). Taken in total, the results are consistent with these drugs inhibiting epithelial activation. Moreover, the results clearly demonstrate a direct effect of NFA and its analogues (Phenyl anthranilic acid derivatives shown in Figure 11), DIDS, and SIDS on mucus over-production, which  
10 is a hallmark of multiple chronic obstructive pulmonary disorders.

*Example 2: NFA inhibits eotaxin production by Caco2 cells activated to over-produce mucin*

Activated LHL4 cells that express and secrete eotaxin have been produced and  
15 used to test for inhibitors of eotaxin production. These cells were assayed *in vitro* for eotaxin by an ELISA technique well known in the art (R&D Systems). As shown in Figure 4, activated LHL4 cells were cultured in the absence (control) or presence of increasing concentrations of niflumic acid (NFA). Significant inhibition of eotaxin production was noted with increasing concentrations of NFA. Similar inhibition was seen  
20 with DIDS and SIDS in an identical experiment. Mad/C3 cells show similar inhibition of eotaxin production by NFA, DIDS, and SIDS. Taken together, these results clearly demonstrate a direct effect of NFA on eotaxin production.

*Example 3: Inhibition of mucin over production in murine models of asthma by  
25 NFA*

Certified virus-free male and female mice of the following strains, DBA, C57B6 and B6D2F1 were purchased from the National Cancer Institute or Jackson Laboratories (Bar Harbor ME). IL-9 transgenic mice (Tg5) and their parent strain (FVB), were obtained from the Ludwig Institute (Brussels, Belgium). Animals were housed in a high-efficiency, particulate filtered air facility and allowed free access to food and water for 3 to  
30

-20-

7 days prior to experimental manipulation. The animal facilities were maintained at 22°C and the light:dark cycle was automatically controlled (10:14 hour light:dark).

*Phenotyping and efficacy of pretreatment.*

5 Animals either received no pretreatment or were sensitized by nasal aspiration of Aspergillus fumigatus antigen to assess the effect of pretreatment on bronchial hyperresponsiveness, composition of bronchoalveolar lavage fluid, mucin production and serum IgE. Mice were challenged with Aspergillus or saline intranasally (on days 0, 7, 14, 21 and 22) and phenotyped 24 hours after the last dose. Sensitized mice were treated on  
10 days 0-21 with either PBS or 100 µg of NFA by intra-tracheal instillation (IT). The inhibition of mucus production and mucin expression in the lung was used to assess the treatment effect of NFA, or could be used to assess the treatment effects of other drug candidates. To determine the bronchoconstrictor response, respiratory system pressure was measured at the trachea and recorded before and during exposure to the drug. Mice  
15 were anesthetized and instrumented as previously described. (Levitt *et al.*, 1988; Levitt and Mitzner, 1989; Kleeberger *et al.*, 1990; Levitt, 1991; Levitt and Ewart, 1995; Ewart *et al.*, 1995). Airway responsiveness is measured to one or more of the following: 5-hydroxytryptamine, acetylcholine, atracurium or a substance-P analog. A simple and repeatable measure of the change in peak inspiratory pressure following  
20 bronchoconstrictor challenge was used which has been termed the Airway Pressure Time Index (APTI) (Levitt *et al.*, 1988; Levitt and Mitzner, 1989). The APTI was assessed by the change in peak respiratory pressure integrated from the time of injection until the peak pressure returns to baseline or plateau. The APTI was comparable to airway resistance, however, the APTI includes an additional component related to the recovery from  
25 bronchoconstriction.

Prior to sacrifice, whole blood was collected for serum IgE measurements by needle puncture of the inferior vena cava in anesthetized animals. Samples were centrifuged to separate cells and serum was collected and used to measure total IgE levels. Samples not measured immediately were frozen at -20°C.

30 All IgE serum samples were measured using an ELISA antibody-sandwich assay. Microtiter plates were coated, 50 µl per well, with rat anti-murine IgE antibody (Southern

-21-

Biotechnology) at a concentration of 2.5 µg/ml in a coating buffer of sodium carbonate-sodium bicarbonate with sodium azide. Plates were covered with plastic wrap and incubated at 4°C for 16 hours. The plates were washed three times with a wash buffer of 0.05% Tween-20 in phosphate-buffered saline, incubating for five minutes for each wash.

5     Blocking of nonspecific binding sites was accomplished by adding 200 µl per well 5% bovine serum albumin in phosphate-buffered saline, covering with plastic wrap and incubating for 2 hours at 37°C. After washing three times with wash buffer, duplicate 50 µl test samples were added to each well. Test samples were assayed after being diluted 1:10, 1:50 and 1:100 with 5% bovine serum albumin in wash buffer. In addition to the test

10    samples, a set of IgE standards (PharMingen) at concentrations from 0.8 ng/ml to 200 ng/ml in 5% bovine serum albumin in wash buffer, were assayed to generate a standard curve. A blank of no sample or standard was used to zero the plate reader (background). After adding samples and standards, the plate was covered with plastic wrap and incubated for 2 hours at room temperature. After washing three times with wash buffer, 50 µl of

15    secondary antibody rat anti-murine IgE-horseradish peroxidase conjugate was added at a concentration of 250 ng/ml in 5% bovine serum albumin in wash buffer. The plate was covered with plastic wrap and incubated 2 hours at room temperature. After washing three times with wash buffer, 100 µl of the substrate 0.5 mg/ml o-phenylenediamine in 0.1 M citrate buffer was added to every well. After 5-10 minutes the reaction was stopped with

20    50 µl of 12.5% sulfuric acid and absorbance was measured at 490 nm on a MR5000 plate reader (Dynatech). A standard curve was constructed from the standard IgE concentrations with antigen concentration on the x axis (log scale) and absorbance on the y axis (linear scale). The concentration of IgE in the samples was interpolated from the standard curve.

25     Bronchoalveolar lavage (BAL) and cellular analysis were preformed as previously described (Kleeberger *et al.*, 1990). Lung histology was carried out after either the lungs were filled with fixative *in situ* and place in formalin, or extracted and immediately frozen in liquid nitrogen. Since prior instrumentation may introduce artifact, separate animals were used for these studies. Thus, a small group of animals was treated in parallel exactly

30    the same as the cohort undergoing various pre-treatments except these animals were not used for other tests aside from bronchial responsiveness testing. After bronchial

-22-

responsiveness testing, lungs were removed and submersed in liquid nitrogen as above. Cryosectioning, staining, and histologic examination was carried out in a manner obvious to those skilled in the art.

NFA, which blocks epithelial cell activation and down-regulates mucin and eotaxin production *in vitro*, was used therapeutically to assess the importance of epithelial cell activation *in vivo* on antigen-induced mucin production, bronchial responsiveness, serum IgE, and airway inflammation as assessed by BAL in mice. The effects of NFA treatment, on airway responsiveness, BAL, mucus production, and serum IgE levels relative to vehicle treated matched controls were determined. Figures 5 and 6 show that NFA is able to suppress airway hyperresponsiveness and BAL lung eosinophilia respectively, however, there was no effect on serum IgE levels. In addition NFA could also suppress the over-production of mucus in the lung caused by exposure to antigen (Figure 7).

Example 4: *Epithelial activation by IL9 in a transgenic mouse produces mucus over-production and mucin gene up-regulation. A model for drug screening.*

Certified virus-free male and female IL9 transgenic mice (IL9TG5-FVB/N) 5-6 weeks of age were bred in our laboratories. Male and female FVB/N mice 5-6 weeks of age were purchased from Jackson Laboratories (Bar Harbor ME). Animals were housed in high-efficiency, particulate filtered air and allowed free access to food and water for 3 to 7 days prior to experimental manipulation. The animal facilities were maintained at 22°C and the light:dark cycle was automatically controlled (10:14 hour light:dark).

*Phenotyping and efficacy of treatment.*

Animals were phenotyped, naïve, or 24 hrs after receiving intra-tracheal (IT) saline (vehicle) treatment, or drugs in the same vehicle as was used in identically treated controls. Mice were treated IT once daily for three days. NFA (100 µg) or antibody to IL-9 were administered in PBS IT. Treatment responses were measured by the assessment of mucin inhibition by histologic exam (PAS staining of greater than 10 sections through the treated and control lungs or western blots of MUC1, MUC2 and MUC3 expression from the same lungs. Figure 8 shows that IL-9 transgenic mice constitutively overproduce mucin as compared to control FVB mice. A decrease from the high levels of constitutive

-23-

mucin production that occurs in the asthmatic IL9 transgenic (Figure 8) (naïve and vehicle control) to levels comparable to the much lower baseline mucin production found in the FVB/N lungs (normal positive control) was considered significant for any drug. The up-regulation of mucus production in the IL9 transgenic is specifically associated with  
5 increased steady-state mRNA levels of MUC2 and MUC5AC as shown by RT-PCR (Figure 9).

Neutralizing IL-9 antibody was shown to produce a significant decrease in mucin production in the IL9 transgenic lungs (Figure 10). NFA also decreased mucin production in this model.

10

Example 5: *Inhibition of mucin over production in murine models of asthma by Talniflumate.*

Certified virus-free male B6D2F1 mice 5-6 weeks of age were purchased from  
15 Jackson Laboratories (Bar Harbor ME). Animals were housed in high-efficiency, particulate filtered air and allowed free access to food and water 5 to 7 days prior to experimental manipulation. The animal facilities were maintained at 22°C and the light:dark cycle was automatically controlled (12:12 hour light:dark).

20           *Phenotyping and efficacy of treatment.*        Animals were fed ad lib either Talniflumate containing mouse chow or regular mouse chow. Animals either received no sensitization or were sensitized by nasal aspiration of Aspergillus fumigatus antigen to assess the effect of pretreatment on bronchial hyperresponsiveness, composition of bronchoalveolar lavage fluid, mucin production and serum IgE. Mice were challenged  
25 with Aspergillus intranasally (on days 0, 7, 16 and 17) and phenotyped 24 hours after the last dose. The inhibition of mucus production in the lung was used to assess the treatment effect of Talniflumate, or could be used to assess the treatment effects of other drug candidates. To determine the bronchoconstrictor response, respiratory system pressure was measured at the trachea and recorded before and during exposure to the drug. Mice  
30 were anesthetized and instrumented as previously described. (Levitt *et al.*, 1988; Levitt and Mitzner, 1989; Kleeberger *et al.*, 1990; Levitt, 1991; Levitt and Ewart, 1995; Ewart *et*

-24-

*al.*, 1995). Airway responsiveness is measured to one or more of the following: 5-hydroxytryptamine, acetylcholine, atracurium or a substance-P analog. A simple and repeatable measure of the change in peak inspiratory pressure following bronchoconstrictor challenge was used which has been termed the Airway Pressure Time Index (APTI) (Levitt *et al.*, 1988; Levitt and Mitzner, 1989). The APTI was assessed by the change in peak respiratory pressure integrated from the time of injection until the peak pressure returns to baseline or plateau. The APTI was comparable to airway resistance, however, the APTI includes an additional component related to the recovery from bronchoconstriction. Bronchoalveolar lavage (BAL) and cellular analysis were preformed as previously described (Kleeberger *et al.*, 1990). Lung histology was carried out after the lungs were harvested and immediately frozen in liquid nitrogen. After bronchial responsiveness testing, lungs were removed and submersed in liquid nitrogen as above. Cryosectioning, staining, and histologic examination was carried out in a manner obvious to those skilled in the art.

15 Treatment responses were measured by the assessment of mucin inhibition by histologic exam (PAS staining of the treated and control lungs).

Oral treatment with Talniflumate reduced mucin staining. Figure 15A shows the PAS staining in mouse lung obtained from Asp-sens mice that were fed regular mouse chow. Figure 15B shows the results obtained from Asp-sens mice fed Talniflumate containing chow. Figure 16 shows the results of feeding talniflumate coated mouse chow on lung eosinophilia determined by bronchoalveolar lavage. Talniflumate reduced the number of eosinophilic cells obtained from mice sensitized to *Aspergillus fumigatus* as compared to sensitized mice fed standard mouse chow.

25 Example 6: *Overexpression of ICACC-1 in epithelium cell lines enhances mucin production*

NCI-H292 cells, a human pulmonary mucoepidermoid carcinoma cell line, were purchased from the American Type Culture Collection (Manassas VA) and cultured in RPMI1640 medium supplemented with 10% FBS and 1% penicillin/streptomycin. 30 The cells were grown in a humidified, air-containing incubator, supplemented with 5% CO<sub>2</sub> at 37°C. Stable NCI-H292 cell lines over-expressing

-25-

hICACC-1 were established by transfection of pcDNA3-hICACC-1 using a Fujin Transfection kit according to the manufacture's instruction (Boehringer-Mannheim). A control cell line was produced, NCI-H292/ctl, by the transfection of pcDNA3 (ctl) into the NCI-H292 cell line using the same procedure. Expression of the hICACC-1 gene was 5 confirmed for the pcDNA3-hICACC-1 transfected by Northern analysis.

For s-ELLA (specific enzyme linked lectin assay), cells were plated in 24-well tissue culture plates and incubated for 72 hours to confluence. Supernatants were transferred into 96-well plates pre-coated with 1 µg/ml anti-MUC5A/C antibody (New marker, Fremont CA) and blocked with 1% BSA. Antibody bound MUC5A/C was then 10 detected with HRP-lectin (Sigma).

For RT-PCR total RNA was isolated from cell lines using Trizol reagent (Gibco/BRL) following the manufacturer's protocol. RT-PCR was performed by reverse transcribing 1 µg of total RNA and amplifying cDNA with the appropriate primers by PCR. Products were separated by electrophoreses on 2% agarose gels and visualized by 15 ethidium bromide staining. Primer pairs used to generate human ICACC-1 message were: sense 5'-GGCACAGATCTTCATTGCTA-3' and antisense 5'- GTGAATGCCAGGAATGGTGCT-3' which produce a 182 bp product. Primer pairs used to generate mucin messages are listed in Table 1.

20           Table 1 (Numbers in parentheses refer to oligonucleotide position contained within the published cDNA).

Gene (Accession #)	Sense primer (5' - 3')	Reverse primer (5' - 3')
HMUC1 (J05582)	GCCAGTAGCACTCACCATAAGCTCG (3113-3136)	CTGACAGACAGCCAAGGCAATGAG (3627-3605)
HMUC5AC (AF015521)	GTGGAACCACGATGACAGC (610-629)	TCAGCACATAGCTGCAGTCG (1428-1408)
HPMS2 (U13696)	GGACGAGAAGTATAACTTCG AG (2133-2154)	CATCTCGCTTGTGTTAAGAGC (2505-2485)

NCI-H292 cells express MUC1 constitutively, whereas MUC2 and MUC5A/C mRNA

-26-

Northern blot analysis of pcDNA3-hICACC-1 transfected cells showing an increased expression level for ICACC mRNA.. Western blot analysis of whole cell lysate from ICACC-1 over-expressing clones revealed enhanced MUC2 protein production (Figure 12B). MUC5A/C expression was significantly increased in ICACC-1 over-expressing 5 cells, while MUC1 was unchanged in RT-PCR analyses (Figure 12C). Specific ELLA analysis also revealed the over-production of MUC5A/C protein in ICACC-1 expressing clones compared with the untransfected NCI-H292 cells or cells transfected with empty vector (Figure 12D).

10           *Example 7: Inhibition of Mucus over-production and MUC 5A/C expression in NCI-H292 cells over-expressing hICACC-1*

For the determination of mucous glycoconjugate production, NCI-H292/ctl and NCI-H292/hICACC-1 (AAF 15) cells were cultured in 24-well plates for 3 days. Cells were then fixed with Formalin and mucous glycoconjugates were visualized by AB/PAS staining (Sigma). Although NCI-H292 control cells displayed a basal PAS staining with a few scattered granules (Figure 13A), over-expression of ICACC-1 dramatically increased the number and intensity of PAS positive muco-glycoconjugates (Figure 13B). For chloride channel blockage studies, cells were cultured in the presence of niflumic acid (NFA) (Sigma) at 100 µM concentration, mefanamic acid (MFA) at 125 or 250 µM or 15 talniflumate at 12.5, 25 or 50 µM, or media alone. PAS staining of cells treated with NFA, MFA or talniflumate revealed significantly fewer positive staining muco-glycoconjugates compared with untreated cells (Figures 13C & D and insert of Figure 14). PAS staining of inhibitor treated control cells showed virtually no difference from 20 untreated cells (Figures 13A & C).

25           The IC<sub>50</sub> values for Talniflumate (Figure 14), Nimesulide (Figure 17) and MSI-2079 (Figure 18, the structure of MSI-2079 is shown in Figure 19) were determined on the basis of its inhibition of MUC5A/C secretion in hCLCA1 expressing H292 cells. Confluent cells were treated with the inhibitor at concentrations from 0 through 250 µM in 30 OPTI MEM. Secreted MUC5A/C was detected forty-eight hours after addition of the inhibitor by an ELLA assay as described in Example 5. The IC50 values were determined

with the data analyzing software GraphPad Prism. The insert of Figure 14 shows the intracellular mucin levels in response to Talniflumate treatment detected by PAS staining.

While the invention has been described and illustrated herein by references to various specific materials, procedures and examples, it is understood that the invention is 5 not restricted to the particular combinations of material and procedures selected for that purpose. Numerous variations of such details can be implied as will be appreciated by those skilled in the art. All patents, patent applications and other references cited throughout this application are herein incorporated by reference in their entirety.

10

## REFERENCES

The following references are herein incorporated by reference in their entirety, as are all references, patents or patent applications referred to in this application:

Aikawa T, Shimura S, Sasaki H, Ebina M and Takishima T. Marked goblet cell 15 hyperplastic with mucus accumulation in the airways of patients who died of severe acute asthma attack. *Chest*, 101, 916-21, 1992.

Alexander AG, Barnes NC and Kay AB. Trial of cyclosporin in corticosteroid-dependent chronic severe asthma. *Lancet* 339, 324-328, 1992.

Basle, R., Roche, W. R., Roberts, J. A., and Holgate, S. T. Cellular events in the 20 bronchi in mild asthma and after bronchial provocation. *Am Rev Respir Dis* 139 , 806-17, 1989.

Borchers MT, Wesselkamper S, Wert SE, Shapiro SD and Leikauf GD. Monocyte inflammation augments acrolein-induced Muc5ac expression in mouse lung. *Am J Physiol*, 277(3 Pt 1), L489-97, 1999.

25 Bosque, J., Chanez, P., Lacoste, J. Y., Barneon, G., Ghavanian, N., Enander, I., Venge, P., Ahlstedt, S., Simony-Lafontaine, J., Godard, P., and *et al.* Eosinophilic inflammation in asthma [see comments]. *N Engl J Med* 323, 1033-9, 1990.

Burrows B, Sears MR, Flannery EM, Herbison GP and Holdaway MD. Relationship of bronchial responsiveness assessed by methacholine to serum IgE, lung 30 function, symptoms and diagnoses in 11-year-old New Zealand children. *J. Allergy Clin. Immunol.* 90, 376-385, 1992.

-28-

Burrows B, Martinez FD, Halonen M, Barbee RA and Cline MG. Association of asthma with serum IgE levels and skin-test reactivity to allergens. *New Eng. J. Med.* 320, 271-277, 1989.

Cardell BS and Pearson RSB. Death in asthmatics. *Thorax* 14, 341-52, 1959.

5 Chu JW and Sharom FJ. Glycophorin A interacts with interleukin-2 and inhibits interleukin-2-dependent T-lymphocyte proliferation. *Cell. Immunol.* 145, 223-239, 1992.

Clifford RD, Pugsley A, Radford M and Holgate ST. Symptoms, atopy and bronchial response to methacholine in parents with asthma and their children. *Arch. Dis. Childhood* 62, 66-73, 1987.

10 Cutz E, Levison H and Cooper DM. Ultrastructure of airways in children with asthma. *Histopathology*, 2, 407-21, 1978.

Dugas B, Renauld JC, Pene J, Bonnefoy J, Peti-Frere C, Braquet P, Bosque J, Van Snick J, Mencia-Huerta JM. Interleukin-9 potentiates the interleukin-4-induced immunoglobulin (IgG, IgM and IgE) production by normal human B lymphocytes. *Eur. J. Immunol.* 23, 1687-1692, 1993.

15 Dunnill MS. The pathology of asthma, with special reference to changes in the bronchial mucosa. *J Clin Invest*, 13, 27-33, 1960.

Dunnill MS, Massarella GR and Anderson JA. A comparison of the quantitative anatomy of the bronchi in normal subjects, in asthmaticus, in chronic bronchitis, and in 20 emphysema. *Thorax*, 24, 176-9, 1969.

Eklund KK, Ghildyal N, Austen KF and Stevens RL. Induction by IL-9 and suppression by IL-3 and IL-4 of the levels of chromosome 14-derived transcripts that encode late-expressed mouse mast cell proteases. *J. Immunol.* 151, 4266-4273, 1993.

Eng PA, Morton J, Douglass JA, Riedler J, Wilson J and Robertson CF. Short-term 25 efficacy of ultrasonically nebulized hypertonic saline in cystic fibrosis. *Pediatr Pulmonol.* 21, 77-83, 1996.

Earle BV. Fatal bronchial asthma. *Thorax* 8, 195-206, 1953.

Ewart S, Levitt RC and Mitzner W. Respiratory system mechanics in mice measured by end-inflation occlusion. *J. Appl. Phys.* 79, 560-566, 1995.

30 Gergen PJ and Weiss KB. The increasing problem of asthma in the United States. *Am. Rev. Respir. Dis.* 146, 823-824, 1992.

-29-

Gergen PJ. The association of allergen skin test reactivity and respiratory disease among whites in the U.S. population. Arch. Intern. Med. 151, 487-492, 1991.

Glynn AA and Michaels L. Bronchial biopsy in chronic bronchitis and asthma. Thorax, 15, 142-53, 1960.

5 Holgate, S. T., Lackie, P. M., Davies, D. E., Roche, W. R., and Walls, A. F. The bronchial epithelium as a key regulator of airway inflammation and remodeling in asthma. Clin Exp Allergy 29 Suppl 2, 90-5, 1999.

10 Halonen M, Stern D, Taussig LM, Wright A, Ray CG and Martinez FD. The predictive relationship between serum IgE levels at birth and subsequent incidences of lower respiratory illnesses and eczema in infants. Am. Rev. Respir. Dis. 146, 666-670, 1992.

Jeffery PK. Morphology of the airway wall in asthma and in chronic obstructive pulmonary disease. Am Rev Respir Dis, 143, 1152-8, 1991.

15 Kleeberger SR, Bassett DJ, Jakab GJ and Levitt RC. A genetic model for evaluation of susceptibility to ozone-induced inflammation. Am. J. Physiol. 258, L313-320, 1990.

Levitt RC and Ewart SL. Genetic susceptibility to atracurium-induced bronchoconstriction. Am. J. Respir. Crit. Care. Med. 151, 1537-1542, 1995.

20 Levitt RC. Understanding biological variability in susceptibility to respiratory disease. Pharmacogenetics 1, 94-97, 1991.

Levitt RC and Mitzner W. Autosomal recessive inheritance of airway hyper-reactivity to 5-hydroxytryptamine. J. Appl. Physiol. 67, 1125-1132, 1989.

Levitt RC, Mitzner W *et al.* Expression of airway hyper-reactivity to acetylcholine as a simple autosomal recessive trait in mice. FASEB J. 2, 2605-2608, 1988.

25 Louahed J, Kermouni A, Van Snick J and Renaud JC. IL-9 induces expression of granzymes and high affinity IgE receptor in murine T helper clones. J. Immunol. 154, 5061-5070, 1995.

Louahed J, Toda M, Jen J, Hamid Q, Renaud JC, Levitt RC and Nicolaides NC. Interleukin-9 up-regulates mucus expression in the airways. Accepted in The American 30 Journal of Respiratory Cell and Molecular Biology, 12/21/99.

-30-

Marsh DG, Meyers DA and Bias WB. The epidemiology and genetics of atopic allergy. *New Eng. J. Med.* 305, 1551-1559, 1982.

Molinoff P *et al.*, Goodman and Gilman's *The Pharmacologic Basis of Therapeutics*, MacMillan Publishing Company, New York NY, 1995.

5 McLane MP, Tepper J, Weiss C, Tomer Y, Taylor RE, Tumas D, Zhou Y, Haczku A, Nicolaides NC and Levitt, RC. Lung delivery of an Interleukin-9 antibody treatment inhibits airway hyper-responsiveness (AHR), BAL eosinophilia, mucin production and serum IgE elevation to natural antigens in a murine model of asthma. Abstract for AAAAI meeting: 3/3-3/8/2000 in San Diego, CA and for ATS/ALA meeting: 5/5/2000 in Toronto, Canada.

Paillasse, R. The relationship between airway inflammation and bronchial hyperresponsiveness. *Clin Exp Allergy* 19, 395-8, 1989.

15 Petit-Frere C, Dugas B, Braquet P, Mencia-Huerta JM. Interleukin-9 potentiates the interleukin-4-induced IgE and IgG1 release from murine B lymphocytes. *Immunology* 79, 146-151, 1993.

Polito, A. J., and Proud, D. Epithelia cells as regulators of airway inflammation. *J Allergy Clin Immunol* 102, 714-8, 1998.

Salvato G. Some histologic changes in chronic bronchitis and asthma. *Thorax*, 23, 168-72, 1968.

20 Sears MR, Burrows B, Flannery EM, Herbison GP, Hewitt CJ and Holdaway MD. Relation between airway responsiveness and serum IgE in children with asthma and in apparently normal children. *New Engl. J. Med.* 325(15), 1067-1071, 1991.

25 Takahashi K, Mizuno H, Ohno H, Kai H, Isohama Y, Takahama K, Nagaoka and Miyata T. Effects of SS320A, a new cysteine derivative, on the change in the number of goblet cells induced by isoproterenol in rat tracheal epithelium. *Jpn J Pharmacol*, 77, 71-77, 1998.

Takizawa, H. Airway epithelial cells as regulators of airway inflammation (Review). *Int J Mol Med* 1, 367-78, 1998.

30 Temann, U. A., Geba, G. P., Rankin, J. A., and Flavell, R. A. Expression of interleukin 9 in the lungs of transgenic mice causes airway inflammation, mast cell hyperplasia, and bronchial hyperresponsiveness. *J Expt Med* 188, 1307-20, 1998.

-31-

Voynow JA and Rose MC. Quantitation of mucin mRNA in respiratory and intestinal epithelial cells. Am J Respir Cell Mol Biol, 11, 742-750, 1994.

Voynow JA, Young LR, Wang Y, Horger T, Rose MC and Fischer BM.  
Neutrophil elastase increases MUC5AC mRNA and protein expression in respiratory  
5 epithelial cells. Am J Physiol, 276(5 Pt 1), L835-43, 1999.

**What is claimed is:**

1. A method of treating a subject with a disease characterized by the production of mucin, comprising administering to the subject an effective amount of a composition comprising at least one compound that decreases mucin synthesis or levels in the subject.
2. A method of claim 1, wherein the mucin synthesis is chloride channel dependent.
3. A method of claim 2, wherein the compound decreases mucin synthesis in cells that express an ICACC chloride channel.
4. A method of claim 1, wherein the compound is selected from a group consisting of analogues and derivatives of anthranilic acid, analogues and derivatives of 2-amino-nicotinic acid, analogues and derivatives of 2-amino-phenylacetic acid, bendroflumethiazide, analogues and derivatives of aminoquinolines, salts thereof and prodrugs thereof.
5. A method of claim 4, wherein the compound is selected from the group consisting of talniflumate, flufenamic acid, niflumic acid, mefenamic acid, bendroflumethiazide, N-(3-fluorobenzyl)-3-aminoquinoline, salts thereof, derivatives thereof and prodrugs thereof.
6. A method of claim 5, wherein the composition comprises talniflumate, a talniflumate derivative, a salt thereof or a prodrug thereof.
7. A method of claim 4, wherein the composition is administered by inhalation.

-33-

8. A method of claim 7, wherein the composition is in the form of a liquid.
9. A method of claim 7, wherein the composition is in the form of a powder.
- 5 10. A method of claim 8, wherein the liquid is aerosolized.
11. A method of claim 1, wherein the composition further comprises at least one expectorant, mucolytic agent, antibiotic or decongestant agent.
- 10 12. A method of claim 11, wherein the expectorant is guaifenesin.
13. A method of claim 1, wherein the composition further comprises at least one stabilizing agent, absorption-enhancing agent or flavoring agent.
- 15 14. A method of claim 13, wherein the stabilizing agent is cyclodextran.
15. A method of claim 13, wherein the absorption-enhancing agent is chitosan.
16. A method of any one of claims 1-15, wherein the disease is selected from  
20 the group consisting of a chronic obstructive pulmonary disease (COPD), an inflammatory lung disease, cystic fibrosis and an acute or chronic infectious disease.
17. A method of claim 16, wherein the composition is administered via  
25 inhalation.
18. A method of claim 17, wherein the composition is administered via inhalation to the lungs or nasal passages.
19. A method of claim 16, wherein the COPD is selected from the group  
30 consisting of emphysema, chronic bronchitis and asthma.

-34-

20. A therapeutic composition formulated for inhalation delivery to the lungs, comprising an amount effective to decrease mucin production or levels of at least one compound selected from the group consisting of talniflumate, flufenamic acid, niflumic acid, mefenamic acid, N-(3-fluorobenzyl)-3-aminoquinoline, salts thereof, derivates 5 thereof and prodrugs thereof.

21. A therapeutic composition of claim 20, wherein the composition comprises talniflumate, a talniflumate derivative, a salt thereof or a prodrug thereof.

10 22. A therapeutic composition of claim 20, wherein the composition is in the form of a liquid.

23. A therapeutic composition of claim 20, wherein the composition is in the form of a powder.

15 24. A therapeutic composition of claim 20, wherein the composition further comprises at least one expectorant, mucolytic agent, antibiotic or decongestant agent.

20 25. A therapeutic composition of claim 24, wherein the expectorant is guaifenesin.

26. A therapeutic composition of claim 20, wherein the composition further comprises at least one stabilizing agent, absorption-enhancing agent or flavoring agent.

25 27. A therapeutic composition of claim 26, wherein the stabilizing agent is cyclodextran.

28. A therapeutic composition of claim 26, wherein the absorption-enhancing agent is chitosan.

-35-

29. An inhalation device comprising a therapeutic composition of any one of claims 20-28.

30. A method of claim 5, wherein the compound is talniflumate.

5

31. A method of claim 5, wherein the compound is selected from a group consisting of N-(3-fluorobenzyl)-3-aminoquinoline, salts thereof, derivatives thereof and prodrugs thereof.

10 32. A method of 4, wherein the compound is administered orally.

33. A method of claim 30, wherein the composition is administered orally.

15 34. A method of treating a subject with a disease characterized by the production of mucin, comprising administering to the subject an effective amount of a composition comprising at least one compound that decreases mucin synthesis or levels in the subject and inhibits a cyclooxygenase enzyme.

20 35. A method of claim 34, wherein the compound specifically inhibits cylooxygenase 2.

25 36. A method according to claim 34, wherein the compound is selected from a group consisting of analogues and derivatives of anthranilic acid, analogues and derivatives of 2-amino-nicotinic acid, analogues and derivatives of 2-amino-phenylacetic acid, bendroflumethiazide, analogues and derivatives of aminoquinolines, salts thereof and prodrugs thereof.

30 37. A method of claim 34, wherein the compound is selected from the group consisting of talniflumate, flufenamic acid, niflumic acid, mefenamic acid, bendroflumethiazide, N-(3-fluorobenzyl)-3-aminoquinoline, salts thereof, derivatives thereof and prodrugs thereof.

-36-

38. A method of claim 34, wherein the composition comprises talniflumate, a talniflumate derivative, a salt thereof or a prodrug thereof.


5 39. A method of claim 34, wherein the composition comprises N-(3-fluorobenzyl)-3-aminoquinoline, salts thereof, derivatives thereof and prodrugs thereof.

40. A method of claim 34, wherein the composition is formulated for inhalation delivery to the lung.

10


41. A method of claim 34, wherein the composition is formulated for oral delivery.

1/20




**FIG. 1D**


2/20




3/20

**FIG. 3**


4/20

**FIG. 4**

5/20

**FIG. 5**

6/20



7/20

FIG. 7



naive Af + PBS Af + PBS + NFA

8/20

X 100





FIG. 8


FVB

L9 Transgenic


9/20

**FIG. 9**





10/20



11/20


**FIG. 11**

12/20

**FIG. 12A****FIG. 12B****FIG. 12C****FIG. 12D**


13/20

**FIG. 13A**  
NCI-H292/ctl



Medium

**FIG. 13B**  
NCI-H292/icacc



**FIG. 13C**




NFA

**FIG. 13D**



14/20

**FIG. 14**

WO 01/54685

PCT/US01/03078

15/20


FIG. 15A



16/20


FIG. 15B




**FIG. 16**

18/20

FIG. 17




19/20

**FIG. 18**

20/20

**FIG. 19**



## INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US01/03078

## A. CLASSIFICATION OF SUBJECT MATTER

IPC(7) : A61K 31/192, 31/195, 31/443, 31/47/ 31/5415  
US CL : 514/224.2, 313, 350, 567

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 514/224.2, 313, 350, 567

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

STN

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	NGUYEN et al. Secretory effects of ATP on nontransformed dog pancreatic duct epithelial cells. American Journal of Physiology. July 1998, Volume 275, Number 1, (Part 1 of 2), pages G104-G113, see entire document.	1-19, 30-41
X	US 5,875,776 A (VAGHEFI)02 March 1999, see column 14, line 5.	20, 23, 29
--	02 March 1999, see column 14, line 5.	-----
Y		20-29

Further documents are listed in the continuation of Box C.  See patent family annex.

* Special categories of cited documents:	"T"	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"A" document defining the general state of the art which is not considered to be of particular relevance	"X"	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"E" earlier document published on or after the international filing date	"Y"	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"L" document which may throw doubt on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"a"	document member of the same patent family
"O" document referring to an oral disclosure, use, exhibition or other means		
"P" document published prior to the international filing date but later than the priority date claimed		

Date of the actual completion of the international search

19 MARCH 2001

Date of mailing of the international search report

14 MAY 2001

Name and mailing address of the ISA/US

Authorized officer